Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573216 | 1.00 | PARP1 (0.53) | PARP1XDHSLC22A12TDP1MEN1 | |
| SCHEMBL13294905 | 0.85 | PARP1 (0.51) | PARP1XDHSLC22A12KDM4EMAPT | |
| SCHEMBL15616865 | 0.85 | PARP1 (0.51) | PARP1XDHSLC22A12MAPTPTGS2 | |
| SCHEMBL12283527 | 0.79 | PARP1 (0.53) | PARP1XDHSLC22A12MAPTPTGS2 | |
| SCHEMBL1029688 | 0.79 | MAPT (0.50) | PARP1XDHSLC22A12TDP1MEN1 | |
| SCHEMBL30605390 | 0.79 | PARP1 (0.76) | PARP1XDHSLC22A12KDM4EMAPT | |
| SCHEMBL7264853 | 0.79 | PARP1 (0.49) | PARP1XDHSLC22A12KDM4EMAPT | |
| SCHEMBL29089219 | 0.79 | PARP1 (0.76) | PARP1XDHSLC22A12KDM4EMAPT | |
| SCHEMBL4387990 | 0.79 | HTR3A (0.51) | PARP1XDHSLC22A12CYP3A4FABP4 | |
| SCHEMBL29555685 | 0.79 | MAPT (0.50) | PARP1XDHSLC22A12TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | claimed |
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2811993-A2 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2014-12-17 | — | — | EP | claimed |
| WO-2013117744-A9 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-10-03 | — | — | WO | claimed |
| WO-2013117744-A2 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2013-08-15 | — | — | WO | claimed |
| EP-1910275-B1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | NOGRA PHARMA LTD (IE) | 2013-02-13 | — | — | EP | claimed |
| US-8138357-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-03-20 | — | — | US | claimed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | claimed |
| EP-2355810-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | Giuliani International Limited (IE) | 2011-08-17 | — | — | EP | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | NOGRA PHARMA LIMITED (IE) | 2010-12-02 | — | — | US | claimed |
| EP-2222291-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | claimed |
| WO-2010063470-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| WO-2009080828-A2 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | claimed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087708-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PARP1 3886/4885XDH 517/4885SLC22A12 2632/4885 |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | PARP1 4434/4885XDH 2540/4885SLC22A12 1999/4885 |
| US-20100305077-A1 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE | SI, FABP2, NFKBIA | PARP1 4775/4885XDH 3488/4885SLC22A12 1441/4885 |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PARP1 3886/4885XDH 517/4885SLC22A12 2632/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | PARP1 3886/4885XDH 517/4885SLC22A12 2632/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | PARP1 876/4885XDH 233/4885SLC22A12 802/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | PARP1 2013/4885XDH 2865/4885SLC22A12 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.